Cleo SG Files Trademark for Universal Vaccine Development Platform... 'Strengthening Pandemic Response Capabilities'

CreosG announced on the 16th that it has completed the trademark registration for its self-developed universal vaccine development platform, ‘SUV-MAP’. By applying SUV-MAP, it is possible to target various infectious diseases such as viruses, as well as enable rapid pandemic response.

SUV-MAP is a vaccine development platform based on recombinant VSV vector technology that attenuates the cytotoxicity of the ‘matrix protein’ through gene recombination mutation technology. By applying VSV technology, genes are loaded onto the vector (carrier), and an immune system can be formed through immune responses to the target expressed substances. CreosG has developed a platform capable of rapidly producing vaccine candidates within 5 months in the event of a pandemic by utilizing its accumulated gene synthesis capabilities.

CreosG has advanced vaccine development technologies while developing various vaccines. It has completed preclinical studies for a total of six vaccine pipelines including COVID-19, △AIDS △MERS △Zika △Crimean-Congo hemorrhagic fever △Severe fever with thrombocytopenia syndrome (SFTS) △Hemorrhagic fever with renal syndrome (HFRS). All national projects related to vaccine development were conducted jointly with the International Vaccine Institute (IVI), an international organization under the UN, and during the COVID-19 pandemic, it signed a contract with IVI for preclinical research services on the COVID-19 vaccine.

CreosG plans to accelerate vaccine development by directly leading it centered on SUV-MAP. It is not only speeding up the commercialization of existing pipelines but also diversifying application areas. Alongside the ongoing Phase 2 clinical trial of the AIDS vaccine ‘SAV001’ in the United States, it is also conducting research and development on combination vaccines using SUV-MAP as a new strategy.

A company representative said, “Since we have verified safety and efficacy while developing various vaccines including COVID-19, SUV-MAP can be immediately applied in the event of a pandemic,” adding, “In particular, the COVID-19 vaccine and the SFTS/HFRS bivalent vaccine using SUV-MAP showed excellent immune responses, confirming relatively high neutralizing antibody responses.”

He continued, “SUV-MAP’s advantage is that it drastically shortens the vaccine development process, enabling rapid response to pandemics,” and added, “Because it can be applied not only to viruses but also to various vaccines such as bacteria, we will further strengthen the vaccine pipeline centered on SUV-MAP.”